http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2006133534-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate | 2005-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2008-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2006133534-A |
| titleOfInvention | APPLICATION OF METRONIDAZOLE FOR THE PRODUCTION OF THE PHARMACEUTICAL COMPOSITION INTENDED FOR THE TREATMENT OF PATHOLOGIES RELATED TO INTERLEUKIN 8 TYPE RECEPTORS IN AND / OR THE RASAR RECIPE TYPE 1 |
| abstract | 1. The use of metronidazole to obtain a pharmaceutical composition intended for the treatment of pathologies in which at least one receptor is selected, selected from the group comprising the IL-8RB receptor and the PAC-1.2 receptor. The use according to claim 1, characterized in that metronidazole modulates the binding of at least one natural ligand to its receptor, said receptor selected from the group consisting of IL-8RB receptor and PAC-1.3 receptor. The use according to claim 1, characterized in that the pathology in which at least one receptor is selected from the group comprising the IL-8RB receptor and the PAC-1 receptor is rosacea. The use according to claim 1, characterized in that the pharmaceutical composition is a dermatological composition for topical application. The use according to claims 1 to 4, characterized in that the composition is intended for the treatment of at least one stage of rosacea. The use according to claim 5, characterized in that the composition is intended for the treatment of the first stage of rosacea. The use according to claim 5, characterized in that the composition is intended for the treatment of the second stage of rosacea. The use according to claim 5, characterized in that the composition is intended for the treatment of the third stage of rosacea. The use according to claim 5, characterized in that the composition is intended for the treatment of the fourth stage of rosacea. The use according to claim 1, characterized in that the composition contains from about 0.0001 to 20% metronidazole, preferably from 0.1 to 2% metronidazole, more preferably from about 0.75 to 1% by weight metronidazole. The use according to claim 1, characterized in that the composition further comprises another active substance selected from |
| priorityDate | 2004-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.